Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Feb 04, 2026
CME vs SPGI Stock Comparison: Q4 Earnings Preview as Trading Volumes Meet Data Demand

CME vs SPGI Stock Comparison: Q4 Earnings Preview as Trading Volumes Meet Data Demand

Key Takeaways

  • CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B.

  • Trading Activity: CME’s full-year 2025 average daily volume (ADV) hit 28.1M contracts, up 6% YoY, signaling robust derivatives demand.

  • S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.

  • Business Models: CME thrives on transaction-based volume and clearing fees, while SPGI benefits from subscription-driven, recurring revenue.

  • Investor Focus: CME’s 2026 fee guidance, volume outlook, and market volatility resilience versus SPGI’s premium margins and subscription growth.

Why This Comparison Matters

CME and SPGI operate at different intersections of financial services:

  • CME captures volatility-driven profits from derivatives trading, clearing, and market data.

  • SPGI leverages high-margin analytics, ratings, and indices, delivering predictable, subscription-backed cash flows.

The upcoming earnings releases provide insight into volume-driven growth versus stable, margin-rich subscription revenue, aiding investors in positioning for rate volatility, trading demand, and data-driven financial services.

CME Earnings Focus

CME’s Q4 and full-year 2025 results (pre-market, February 4) are expected to show:

  • Adjusted EPS: $2.75 (+9.1% YoY from $2.52)

  • Revenue: $1.6–$1.64B (+~7%)

  • Key Drivers:

    • Average daily volume (ADV): Q4 record of 27.4M contracts

    • Clearing and transaction fees: ~$1.3B

    • Market data revenue growth and 2026 fee guidance

  • Volume Highlights: Metals +34% and energy contracts showing volatility-fueled growth; interest rate contracts also key.

  • Historical Context: CME has beaten EPS estimates in the last four quarters, though stock reactions are often muted, reflecting market anticipation.

SPGI Context and Earnings Relevance

SPGI’s Q4 earnings on February 10, 2026, follow a strong Q3 showing:

  • Revenue: ~$3.89B (+9%)

  • Adjusted EPS: $4.73 (vs $4.40 consensus)

  • Growth Drivers: Ratings and Market Intelligence; adjusted operating margins ~52%

  • Investor Takeaways: SPGI’s subscription-heavy model contrasts CME’s volatility-driven revenue, providing predictable cash flows and high margins.

Insights:

  • CME offers a volume-driven, high-beta play on derivatives markets, benefiting from volatility spikes.

  • SPGI provides premium valuation with steady recurring revenue, insulating it from short-term market swings.

  • Risks: CME faces competition and regulatory scrutiny; SPGI is sensitive to deal flow and economic cycles.

Tickeron AI Perspective

Tickeron AI Verdict

Tickeron’s AI models lean toward CME pre-earnings, highlighting:

  • Record volumes and consistent EPS beats (4/4 quarters)

  • Undervalued P/E (~26x) relative to premium SPGI (~40x)

  • Short-term probabilistic edge in volatility-driven trading, assuming positive guidance

SPGI remains attractive for margin stability and subscription growth, but CME’s derivatives exposure and guidance leverage provide potential for near-term outperformance.

Disclaimers and Limitations

Related Ticker: CME, SPGI

CME's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CME turned positive on July 06, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 22, 2026. You may want to consider a long position or call options on CME as a result. In of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CME moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CME crossed bullishly above the 50-day moving average on July 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 267 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

CME broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.631) is normal, around the industry mean (5.409). P/E Ratio (22.713) is within average values for comparable stocks, (25.060). CME's Projected Growth (PEG Ratio) (4.699) is very high in comparison to the industry average of (2.200). CME has a moderately high Dividend Yield (0.042) as compared to the industry average of (0.019). CME's P/S Ratio (14.286) is slightly higher than the industry average of (7.717).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are CME Group (NASDAQ:CME).

Industry description

The financial publishing /services sector includes companies that provide informational products and services that are of value to investors, financial/analytics professionals and other interested readers. The products include real-time stock quotes, financial news and analyses. Think S&P Global, Inc., Moody`s Corporation, Thomson-Reuters Corp and IHS Markit Ltd. Information is critical in making financial or investment decisions, and what makes this industry’s output relevant at all times, across various economic conditions.

Market Cap

The average market capitalization across the Financial Publishing/Services Industry is 38.91B. The market cap for tickers in the group ranges from 1.9M to 121.44B. SPGI holds the highest valuation in this group at 121.44B. The lowest valued company is BTOG at 1.9M.

High and low price notable news

The average weekly price growth across all stocks in the Financial Publishing/Services Industry was 0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -9%. MORN experienced the highest price growth at 12%, while BTOG experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Financial Publishing/Services Industry was 72%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 55
Profit Risk Rating: 79
Seasonality Score: -36 (-100 ... +100)
View a ticker or compare two or three
CME
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of securities and commodity exchanges

Industry FinancialPublishingServices

Profile
Details
Industry
Investment Banks Or Brokers
Address
20 South Wacker Drive
Phone
+1 312 930-1000
Employees
3875
Web
https://www.cmegroup.com
Interact to see
Advertisement
Chevron’s upcoming Q4 report highlights its first full quarters integrating Hess, following record Q3 production of 4.1 million barrels of oil equivalent per day (MMboe/d). Comparing CVX with ExxonMobil and Shell provides insight into how each supermajor is navigating a volatile oil market with prices hovering below $60 per barrel.
SoFi Technologies is set to report Q4 and full-year 2025 earnings on January 30, 2026, closing out a pivotal year for the digital finance platform. With its fiscal year ending December 31, the report follows a strong Q3 that featured record net revenue of $962 million and member growth to 12.6 million, a 35% year-over-year increase.
ASML reported Q4 2025 net sales of $9.7 billion, gross margin of 52.2%, net income of $2.8 billion, and record net bookings of $13.2 billion, including $7.4 billion in EUV orders.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics. Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
NIO Inc. (NIO) produced its one-millionth vehicle this week at its Hefei facility, closing out a record 2025 delivery total of 326,028 units, up 46.9% year over year. The milestone, announced January 6, reflects accelerating demand for core models such as the ES8 SUV and newer brands ONVO and Firefly.
Faraday Future Intelligent Electric Inc. (FFAI) shares traded near $1.02 this week following announcements of a non-binding $10 million stock purchase term sheet with AIxCrypto (AIxC) and preparations for a Stockholders’ Day on January 7, 2026. Trading volume spiked amid broader EV volatility, highlighting investor attention on FFAI’s pivot toward AI-enhanced mobility and robotics.
BTQ Technologies Corp. (BTQ), formerly BTQQF, launched the Bitcoin Quantum testnet this week—the first quantum-safe Bitcoin fork, 17 years after Bitcoin’s genesis block. The move coincided with inclusion in the $524.5 million VanEck Quantum Computing UCITS ETF, boosting European investor visibility.
VEU targets large- and mid-cap ex-U.S. stocks with ~3,800 holdings. VXUS offers broad all-cap exposure, including ~8,600 stocks across small-, mid-, and large-cap companies.
Apple (AAPL) reports Q1 FY2026 earnings on January 29, with consensus revenue at $138.5B and EPS at $2.67, supported by strong demand for iPhone 17 models, higher average selling prices, and continued Services growth. Microsoft (MSFT) reports Q2 FY2026 on January 28, expecting $80.3B revenue and $3.91 EPS, driven by Azure AI adoption and enterprise cloud expansion, though elevated capex spending (~$35B/quarter) remains under scrutiny.
Visa Inc. (V), the global payments network leader, reports Q1 FY2026 earnings on January 29, 2026, for the period ending December 31, 2025. This marks the start of FY2026 following a strong FY2025, where net revenue reached $40 billion (+11%) and EPS climbed to $11.47 (+14%). Investors are watching closely for insights into consumer spending, cross-border travel recovery, and digital payment adoption.
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.